Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...
(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...
Issued on behalf of Oncolytics Biotech Inc. "With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep's potential in HR+/HER2- metastatic breast cancer,” said ...
Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...
TD Bank was already in hot water for its anti-money-laundering failures. Now a former employee in the bank's AML department is facing a felony charge in connection with a separate alleged criminal ...
to share information to strengthen the AML/CFT framework of the country. The FIU has entered into 45 MOUs with foreign counterparts as well.
LONDON (Reuters) - Aston Martin 's (L:AML) first sport utility vehicle rolled off the production line on Thursday, key to hopes of a turnaround at the luxury carmaker ...
Investing.com - European stock markets edged higher Wednesday, with the focus squarely on the conclusion of the latest U.S. Federal Reserve policy-setting meeting. At ...